FDA fines Globus Medical and CEO $1M for selling rejected bone graft products

February 29, 2012 by MassDevice staff

Orthopedics device maker Globus Medical and its CEO agree to pay a $1 million fine after an FDA inspection finds the company marketing bone graft products that the agency had denied for the U.S. market.

Globus Medical logo

Orthopedics device maker Globus Medical will pay $1 million, including a fine for its chief officer, to settle FDA charges that the company marketed bone graft products without getting the agency's approval.

The fine includes $550,000 in penalties and a $450,000 charge for Globus CEO David Paul.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.